{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:51:12Z","timestamp":1793757072472,"version":"4.6.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,17]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Although chimeric antigen receptor (CAR) T-cell (CAR-T) therapy has revolutionized the treatment of B-cell malignancies, many patients relapse and therefore strategies to improve antitumor immunity are needed. We previously designed a novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high response rates but relapse was common. Interleukin-15 (IL15) induces proliferation of diverse immune cells and can augment lymphocyte trafficking. Here, we report the results of a phase 1 clinical trial of the first combination of a novel recombinant polymer-conjugated IL15 receptor agonist (NKTR-255), with CAR19-22, in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Eleven patients were enrolled, 9 of whom successfully received CAR19-22 followed by NKTR-255. There were no dose-limiting toxicities, with transient fever and myelosuppression as the most common possibly related toxicities. We observed favorable efficacy with 8 of 9 patients (89%) achieving measurable residual disease\u2013negative remission. At 12 months, progression-free survival for NKTR-255 was double that of historical controls (67% vs 38%). We performed correlative analyses to investigate the effects of IL15 receptor agonism. Cytokine profiling showed significant increases in IL15 and the chemokines CXCL9 and CXCL10. The increase in chemokines was associated with decreases in absolute lymphocyte counts and CD8+ CAR T cells in the blood and 10-fold increases in cerebrospinal fluid CAR-T cells, suggesting lymphocyte trafficking to tissue. Combining NKTR-255 with CAR19-22 was safe, feasible, and associated with high rates of durable responses. This trial was registered at www.clinicaltrials.gov as #NCT03233854.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024952","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:03:57Z","timestamp":1720199037000},"page":"1689-1698","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-3010","authenticated-orcid":false,"given":"Hrishikesh","family":"Srinagesh","sequence":"first","affiliation":[{"name":"1Division of Hematology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Jackson","sequence":"additional","affiliation":[{"name":"2Division of Hematology\/Oncology, UT Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9979-4434","authenticated-orcid":false,"given":"Nikeshan","family":"Jeyakumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hamilton","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egeler","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Mavroukakis","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-0043","authenticated-orcid":false,"given":"Adam","family":"Kuo","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juancarlos","family":"Cancilla","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Kanegai","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5239-7343","authenticated-orcid":false,"given":"Anne Marijn","family":"Kramer","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"},{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kennedy","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Negrin","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rezvani","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Shizuru","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-3860","authenticated-orcid":false,"given":"Steven","family":"Feldman","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"},{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Lee","sequence":"additional","affiliation":[{"name":"5Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"5Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mario","family":"Marcondes","sequence":"additional","affiliation":[{"name":"5Nektar Therapeutics, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David","family":"Miklos","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"},{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal","family":"Mackall","sequence":"additional","affiliation":[{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA"},{"name":"4Center for Cancer Cell Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"15","key":"2024101715203505100_bib1","first-page":"1650","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"issue":"2","key":"2024101715203505100_bib2","first-page":"354","article-title":"Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"10","key":"2024101715203505100_bib3","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"2024101715203505100_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"2024101715203505100_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"2024101715203505100_bib6","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"2024101715203505100_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","article-title":"Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2024101715203505100_bib8","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1586\/1744666X.2014.973856","article-title":"Interleukin-15 in the treatment of cancer","volume":"10","author":"Waldmann","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"2024101715203505100_bib9","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1084\/jem.20020066","article-title":"Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells","volume":"195","author":"Tan","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"24","key":"2024101715203505100_bib10","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","article-title":"IL-15 and T cell stemness in T cell-based cancer immunotherapy","volume":"75","author":"Pilipow","year":"2015","journal-title":"Cancer Res"},{"issue":"5","key":"2024101715203505100_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2024101715203505100_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024101715203505100_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"16","key":"2024101715203505100_bib14","first-page":"1803","article-title":"Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J\u00a0Clin Orthod"},{"key":"2024101715203505100_bib15","doi-asserted-by":"crossref","first-page":"1165404","DOI":"10.3389\/fimmu.2023.1165404","article-title":"IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"2024101715203505100_bib16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","article-title":"Cooperative armoring of CAR and TCR T cells by T cell\u2013restricted IL15 and IL21 universally enhances solid tumor efficacy","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2024101715203505100_bib17","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1158\/1078-0432.CCR-18-3468","article-title":"IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial\u00a0induced dramatic NK-cell subset expansion","volume":"25","author":"Conlon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024101715203505100_bib18","doi-asserted-by":"crossref","first-page":"e002024","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"2024101715203505100_bib19","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2022008697","article-title":"A\u00a0novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy","volume":"7","author":"Hirayama","year":"2023","journal-title":"Blood Adv"},{"key":"2024101715203505100_bib20","unstructured":"Common terminology criteria for adverse events (CTCAE) | protocol development | CTEP. Accessed 30 January 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"issue":"4","key":"2024101715203505100_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024101715203505100_bib22","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2024101715203505100_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2024101715203505100_bib24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024101715203505100_bib25","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLoS One"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/16\/1689\/2247146\/blood_bld-2024-024952-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/16\/1689\/2247146\/blood_bld-2024-024952-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:21:39Z","timestamp":1729178499000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/16\/1689\/516858\/A-phase-1-clinical-trial-of-NKTR-255-with-CD19-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,10,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024952","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}